GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioInvent International AB (STU:BIX) » Definitions » EV-to-FCF

BioInvent International AB (STU:BIX) EV-to-FCF : -2.85 (As of Apr. 02, 2025)


View and export this data going back to 2013. Start your Free Trial

What is BioInvent International AB EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, BioInvent International AB's Enterprise Value is €98.02 Mil. BioInvent International AB's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 was €-34.36 Mil. Therefore, BioInvent International AB's EV-to-FCF for today is -2.85.

The historical rank and industry rank for BioInvent International AB's EV-to-FCF or its related term are showing as below:

STU:BIX' s EV-to-FCF Range Over the Past 10 Years
Min: -34.57   Med: -5.32   Max: 0.66
Current: -3.01

During the past 13 years, the highest EV-to-FCF of BioInvent International AB was 0.66. The lowest was -34.57. And the median was -5.32.

STU:BIX's EV-to-FCF is ranked worse than
100% of 446 companies
in the Biotechnology industry
Industry Median: 2.72 vs STU:BIX: -3.01

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2025-04-02), BioInvent International AB's stock price is €2.64. BioInvent International AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was €-0.574. Therefore, BioInvent International AB's PE Ratio (TTM) for today is At Loss.


BioInvent International AB EV-to-FCF Historical Data

The historical data trend for BioInvent International AB's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioInvent International AB EV-to-FCF Chart

BioInvent International AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -15.72 -6.36 -20.37 -0.57 -4.31

BioInvent International AB Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.57 -0.22 -3.80 -6.12 -4.31

Competitive Comparison of BioInvent International AB's EV-to-FCF

For the Biotechnology subindustry, BioInvent International AB's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioInvent International AB's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioInvent International AB's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where BioInvent International AB's EV-to-FCF falls into.


;
;

BioInvent International AB EV-to-FCF Calculation

BioInvent International AB's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=98.021/-34.364
=-2.85

BioInvent International AB's current Enterprise Value is €98.02 Mil.
BioInvent International AB's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-34.36 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BioInvent International AB  (STU:BIX) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

BioInvent International AB's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=2.64/-0.574
=At Loss

BioInvent International AB's share price for today is €2.64.
BioInvent International AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.574.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


BioInvent International AB EV-to-FCF Related Terms

Thank you for viewing the detailed overview of BioInvent International AB's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


BioInvent International AB Business Description

Traded in Other Exchanges
Address
Ideongatan 1, Lund, SWE, SE-223 70
BioInvent International AB is a clinical-stage biotech company. It discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently four drug candidates in five ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The company's validated, proprietary F.I.R.S.T technology platform identifies both targets and the antibodies that bind to them, generating many new drug candidates to fuel the company's own clinical development pipeline and providing licensing and partnering opportunities. The company's pipeline portfolio comprises BI-1206, an antagonistic blocking antibody for the treatment of non-Hodgkin's lymphoma, and BI-1808 and BI-1910 (anti-TNFR2) for solid cancers.

BioInvent International AB Headlines

No Headlines